Concepedia

Publication | Open Access

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial

DOIFull Paper Access

46

Citations

27

References

2023

Year

Tim Flaadt, Ruth Ladenstein, Martin Ebinger, Holger N. Lode, Helga Björk Arnardóttir, Ulrike Pöetschger, Wolfgang Schwinger, Roland Meisel, Friedhelm R. Schuster, Michaela Döring,
Journal of Clinical Oncology

Abstract

DB therapy after haplo-SCT in patients with rHR-NB is feasible, with low risk of inducing GvHD, and results in long-term remissions likely attributable to increased antineuroblastoma activity by donor-derived effector cells.

References

YearCitations

Page 1